EU Says Without EMA Approval COVID-19 Boosters May Face Higher Legal Risks: Reuters
European Union countries that decide to use COVID-19 vaccine booster shots may face increased legal risks, the European Commission said.
AstraZeneca’s Drug Shows Promise In Copper Build-Up Genetic Disease
AstraZeneca plc (NASDAQ:AZN) reported high-level results from the FoCus Phase 3 trial evaluating ALXN1840 in Wilson disease. The study met the…
Texas Gov. Greg Abbott Has Banned Vaccine Mandates Of Any Kind In New Executive Order
https://gov.texas.gov/uploads/files/press/EO-GA-39_prohibiting_vaccine_mandates_and_vaccine_passports_IMAGE_08-25-2021.pdf
Thailand-Developed System Can Draw Out More COVID-19 Vaccine Doses: All You Need To Know
Researchers in Thailand have developed a machine to draw out COVID-19 vaccine doses more efficiently and optimize lower-than-expected supplies.
COVID Vaccine Protection Wanes Within Six Months According to UK Researches in Study of Pfizer, AstraZeneca Vaccines
-Reuters
https://www.reuters.com/business/healthcare-pharmaceuticals/covid-jab-protection-wanes-within-six-months-uk-researchers-2021-08-25/
Why Did AstraZeneca’s Alexion Stop Amyotrophic Lateral Sclerosis Trial?
AstraZeneca Inc's (NASDAQ: AZN) newly acquired Alexion division will stop developing a treatment for the neurological disorder amyotrophic lateral sclerosis (ALS) due to lack of efficacy in a late-stage trial.
AstraZeneca’s COVID-19 Antibody Cuts Risk Of Symptomatic Disease By 77%
A new coronavirus antibody treatment developed by AstraZeneca plc (NASDAQ: AZN) reduced the risk of developing the symptomatic disease by 77% compared to placebo.
After FDA Rejection, EMA Approves FibroGen-Astellas’ Roxadustat
The European Commission (EC) has approved FibroGen Inc (NASDAQ:FGEN) and Astellas Pharma’s (OTC:ALPMF) Evrenzo (roxadustat) for anemia caused by chronic kidney disease (CKD),…